Lyra Therapeutics (Lyra Therapeutics) ROCE % : -76.56% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Lyra Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lyra Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -76.56%.

Lyra Therapeutics ROCE % Historical Data

The historical data trend for Lyra Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyra Therapeutics ROCE % Chart

Lyra Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-99.65

-51.83

-77.49

-83.24

-59.98

Lyra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-79.05	-62.36	-63.23	-58.76	-76.56

Lyra Therapeutics ROCE % Calculation

Lyra Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-65.528	/	( ( (109.968 - 14.47)	+	(142.6 - 19.597) )	/ 2 )
	=	-65.528	/	( (95.498	+	123.003)	/ 2 )
	=	-65.528	/	109.2505
	=	-59.98 %

Lyra Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-94.096	/	( ( (142.6 - 19.597)	+	(141.527 - 18.724) )	/ 2 )
	=	-94.096	/	( ( 123.003	+	122.803 )	/ 2 )
	=	-94.096	/	122.903
	=	-76.56 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Lyra Therapeutics (NAS:LYRA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lyra Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Lyra Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyra Therapeutics (Lyra Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyra Therapeutics Inc (NAS:LYRA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Watertown, MA, USA, 02472

Website

https://lyratherapeutics.com

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Executives

Harlan Waksal	director, officer: Executive Chair	WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nbvm Gp, Llc	10 percent owner	950 WINTER STREET, SUITE 4600, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Edward T Anderson	director, 10 percent owner	950 WINTER ST SUITE 4600, WATHAM MA 02451
John E Bishop	officer: Chief Technology Officer	675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Richard Nieman	officer: Chief Medical Officer	C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
C Ann Merrifield	director
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jason Cavalier	officer: Chief Financial Officer	C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Snyderman Nancy Lynn Md	director	37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Pamela E. Nelson	officer: Senior VP, Regulatory Affairs	C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Robert E. Richard	officer: SVP of R&D	C10 LYRA THERAPEUTICS, INC., 1480 ALSENAL WAY, WATERTOWN MA 02472
Soleus Private Equity Fund I, L.p.	10 percent owner	C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Soleus Capital, Llc	10 percent owner	104 FIELD POINT ROAD, FLOOR 2, GREENWICH CT 06830
Polaris Venture Partners Special Founders' Fund V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210